Terms ending in 2032
Every in-force patent on Pharma Cinq, LLC's record whose computed term ends in 2032, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,228,003 | Complement Factor B Analogs and Their Uses In force · High confidence | Pharma Cinq, LLC | In force | High confidence | |
| US 9,533,028 | Complement Factor B Analogs and Their Uses In force · High confidence | Pharma Cinq, LLC | In force | High confidence | |
| US 10,415,026 | Complement Factor B Analogs and Their Uses In force (reinstated) · High confidence | Pharma Cinq, LLC | In force (reinstated) | High confidence | |
| US 10,689,637 | Complement Factor B Analogs and Their Uses In force · High confidence | Pharma Cinq, LLC | In force | High confidence | |
| US 11,001,822 | Complement Factor B Analogs and Their Uses In force · High confidence | Pharma Cinq, LLC | In force | High confidence | |
| US 9,244,073 | Assays for Detecting Enzymatic Activity In force · High confidence | Pharma Cinq, LLC | In force | High confidence | |
| US 9,265,813 | Vectors Encoding Rod-Derived Cone Viability Factor In force · High confidence | Pharma Cinq, LLC | In force | High confidence | |
| US 10,040,835 | Vectors Encoding Rod-Derived Cone Viability Factor In force · High confidence | Pharma Cinq, LLC | In force | High confidence | |
| US 9,213,043 | Clinical Diagnostic System Including Instrument and Cartridge In force · Medium confidence | Pharma Cinq, LLC | In force | Medium confidence | |
| US 9,625,465 | Clinical Diagnostic Systems In force (reinstated) · Medium confidence | Pharma Cinq, LLC | In force (reinstated) | Medium confidence | |
| 1 more term end in 2032 · Pro | |||||
10 of 11 patents shown. Soonest term end first, then patent number.
Pro members see all 11.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.